Abstract 1073TiP
Background
Tumor necrosis factor (TNF) is a potent pro-inflammatory cytokine known to induce an inflammatory response and cell death, and anti-TNF drugs are used to treating autoimmune diseases. TNF has two receptors: TNFR1, which is broadly expressed on many different cell types, and TNFR2, with expression mainly expressed restricted to thein the immune system. TNFR2 is a type I transmembrane protein with typically high expression in myeloid cells and specific T cell subsets. Macrophages and Tregs constitutively express TNFR2. In effector T cells TNFR2 expression is upregulated after T cell receptor stimulation. The role of TNFR2 in inflammation is unclear with both proinflammatory and immunoregulatory roles postulated. TNFR2 is shown to both be important for T reg survival, while simultaneously acting as a potent costimulatory molecule on CD8+ T cells thereby promoting inflammatory activity. Given the costimulatory functions of TNFR2 in different immune cells, TNFR2 has in recent years been suggested as a promising novel target for anticancer treatment. We are developing BI-1910, an agonistic human IgG2 mAb targeting TNFR2. BI-1910 agonizes T cells and mediates CD4+ and CD8+ T cell activation. It binds human TNFR2 selectively but does not block the interaction between the receptor and its ligand, TNF-α. BI-1910 combined with anti-PD-1 showed additive anti-tumor effect in preclinical models, providing rationale to clinically evaluate in combination with pembrolizumab.
Trial design
This is a Phase 1/2a dose escalation clinical trial of BI-1910, as single agent and in combination with pembrolizumab, in subjects with advanced/metastatic solid tumors who progressed after standard therapy. It to establish safety/tolerability profile, pharmacokinetics, pharmacodynamics and preliminary efficacy of BI-1910 as monotherapy and in combination. Phase 1 dose escalation is guided by a BLRM design, planned to enroll up to 34 patients. Phase 2a will be performed in advanced/metastatic NSCLC and HCC patients in parallel cohorts. Safety and efficacy of BI-1910 as monotherapy and in combination will be evaluated at two separate dose levels for dose optimization.
Clinical trial identification
NCT06205706.
Editorial acknowledgement
Legal entity responsible for the study
BioInvent International AB.
Funding
BioInvent International AB.
Disclosure
M. Borggren, P. Holmkvist, I. Karlsson, M. Meller, L. Mårtensson, J. Nilsson, M. Vaapil, J.E. Wallin, I. Teige, B. Frendeus, A. McAllister: Financial Interests, Personal and Institutional, Full or part-time Employment: BioInvent. M. Chisamore: Financial Interests, Personal and Institutional, Full or part-time Employment: MSD/Merck&Co. All other authors have declared no conflicts of interest.
Resources from the same session
1132P - Regorafenib in Caucasian patients with pretreated advanced KIT-mutant melanoma: A dual center case series
Presenter: Iris Dirven
Session: Poster session 04
1133P - Only early adjuvant radiotherapy, particularly of the tumor bed rather than the lymph node region, improves prognosis in Merkel cell carcinoma: Results from the prospective German MCC registry
Presenter: Juergen Becker
Session: Poster session 04
1134P - Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200
Presenter: Celeste Lebbe
Session: Poster session 04
1135P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment of Merkel cell carcinoma
Presenter: Maximilian Haist
Session: Poster session 04
1136P - Cosibelimab in advanced cutaneous squamous cell carcinoma (CSCC): Longer-term efficacy and safety results from pivotal study
Presenter: Eva Muñoz-Couselo
Session: Poster session 04
1137P - Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors
Presenter: Justine Cohen
Session: Poster session 04
1138P - A prospective study of patients with immune checkpoint inhibitor-induced hepatitis: Management outcome and association with liver injury subtype, immune infiltration, and clinical parameters
Presenter: Rikke Holmstroem
Session: Poster session 04
1139TiP - IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma
Presenter: Marcus Butler
Session: Poster session 04
1140TiP - Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
Presenter: Joséphine Janssen
Session: Poster session 04
1210P - Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study
Presenter: Marina Garassino
Session: Poster session 04